CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Clinical trial NCT04603872 · RECRUITING

Trial details

NCT number: NCT04603872
Sponsor: Zhejiang University
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma in Relapse Multiple Myeloma, Refractory Acute Lymphoblastic Leukemia, in Relapse Acute Lymphocytic Leukaemia Refractory Non-Hodgkin's Lymphoma, Relapsed Non-Hodgkin's Lymphoma Refractory

Start date: 2020-11-01
Primary completion: 2023-11-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.